{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T23:47:02Z","timestamp":1773791222966,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T00:00:00Z","timestamp":1455235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jsps.2016.02.002","type":"journal-article","created":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T07:15:19Z","timestamp":1455520519000},"page":"93-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessment of novel oral anticoagulant use within a community teaching hospital"],"prefix":"10.1007","volume":"25","author":[{"given":"Sultan","family":"Alghadeer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Hornsby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"9","key":"10.1016\/j.jsps.2016.02.002_b0005","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism (AMPLIFY)","volume":"369","author":"Agnelli","year":"2013","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jsps.2016.02.002_b0010","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1378\/chest.12-2486","article-title":"Fatal association of mechanical valve thrombosis with dabigatran: a report of two cases","volume":"144","author":"Atar","year":"2013","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.jsps.2016.02.002_b0015","article-title":"Clinical challenges related to novel oral anticoagulants: drug\u2013drug interactions and monitoring","volume":"99","author":"Atlena","year":"2014","journal-title":"Haematologica"},{"issue":"26","key":"10.1016\/j.jsps.2016.02.002_b0020","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism (EINSTEIN)","volume":"363","author":"Bauersachs","year":"2010","journal-title":"New Engl. J. Med."},{"issue":"14","key":"10.1016\/j.jsps.2016.02.002_b0025","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism (EINSTEIN PE)","volume":"366","author":"Buller","year":"2012","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jsps.2016.02.002_b0030","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.amjopharm.2012.02.004","article-title":"Clinical challenges in a patient with dabigatran-induced fatal hemorrhage","volume":"10","author":"Cano","year":"2012","journal-title":"Am. J. Geriatr. Pharmacother."},{"issue":"12","key":"10.1016\/j.jsps.2016.02.002_b0035","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY)","volume":"361","author":"Connolly","year":"2009","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jsps.2016.02.002_b0040","unstructured":"Coumadin (warfarin Sodium), 2011. Prescribing Information. Bristol-Myers Squibb, Inc., Princeton (NJ)."},{"issue":"9","key":"10.1016\/j.jsps.2016.02.002_b0045","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.amjmed.2011.02.009","article-title":"Dabigatran falsely elevates point of care international normalized ratio results","volume":"124","author":"Deremer","year":"2011","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jsps.2016.02.002_b0050","unstructured":"Eliquis (apixaban), 2014. Prescribing Information. Bristol-Myers Squibb Inc., Princeton (NJ) and Pfizer Inc., New York (NY)."},{"issue":"6","key":"10.1016\/j.jsps.2016.02.002_b0055","first-page":"388","article-title":"Dabigatran etexilate linked to fatal gastrointestinal hemorrhage","volume":"16","author":"Feinberg","year":"2014","journal-title":"Isr Med. Assoc. J."},{"issue":"2","key":"10.1016\/j.jsps.2016.02.002_b0060","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1016\/j.jemermed.2012.02.042","article-title":"Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency","volume":"44","author":"Felows","year":"2013","journal-title":"J. Emerg. Med."},{"issue":"14","key":"10.1016\/j.jsps.2016.02.002_b0065","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.2146\/ajhp110644","article-title":"Epistaxis associated with dabigatran in an elderly patient with reduced creatinine clearance","volume":"69","author":"Freshour","year":"2012","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.jsps.2016.02.002_b0070","unstructured":"Health Department of New South Wales (NSW) Government, Safety Alerts for Professionals [Internet]. North Sydney NSW (Australia): the NSW Ministry of Health [updated 2014 Jun 10, cited 2014 Sep 30]. Available from: <http:\/\/www.health.nsw.gov.au\/sabs\/Documents\/2014-sn-002.pdf>."},{"issue":"5","key":"10.1016\/j.jsps.2016.02.002_b0075","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.athoracsur.2013.03.043","article-title":"Thromboembolism in a patient with a mechanical mitral valve during anticoagulation with dabigatran etexilate","volume":"96","author":"Kuwauchi","year":"2013","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.jsps.2016.02.002_b0080","first-page":"w13906","article-title":"Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus","volume":"144","author":"Lakatos","year":"2014","journal-title":"Swiss Med Wkly"},{"issue":"9717","key":"10.1016\/j.jsps.2016.02.002_b0085","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.jsps.2016.02.002_b0090","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. (ADVANCE-3)","volume":"363","author":"Lassen","year":"2010","journal-title":"New Engl. J. Med."},{"issue":"9855","key":"10.1016\/j.jsps.2016.02.002_b0095","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(12)60986-6","article-title":"Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial","volume":"380","author":"Lopes","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jsps.2016.02.002_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajem.2012.08.015","article-title":"Fatal dabigatran toxicity secondary to acute renal failure","volume":"31","author":"Maddry","year":"2013","journal-title":"Am. J. Emerg. Med."},{"issue":"10","key":"10.1016\/j.jsps.2016.02.002_b0105","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET AF)","volume":"365","author":"Patel","year":"2011","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jsps.2016.02.002_b0110","unstructured":"Pradaxa (dabigatran etexilate), 2013. Prescribing Information. BoehringerIngelheim Pharmaceuticals, Inc., Ridgefield (CT)."},{"issue":"17","key":"10.1016\/j.jsps.2016.02.002_b0115","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.jacc.2012.06.039","article-title":"Mechanical valve thrombosis with dabigatran","volume":"60","author":"Price","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"52","key":"10.1016\/j.jsps.2016.02.002_b0120","first-page":"A6568","article-title":"Pulmonary embolism due to interaction between rivaroxaban and carbamazepine","volume":"157","author":"Risselada","year":"2013","journal-title":"Nederlands Tijdschr Geneeskd"},{"issue":"19","key":"10.1016\/j.jsps.2016.02.002_b0125","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2146\/ajhp120518","article-title":"Fatal bleeding associated with dabigatran","volume":"70","author":"Schaeffer","year":"2013","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"24","key":"10.1016\/j.jsps.2016.02.002_b0130","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER)","volume":"361","author":"Schulman","year":"2009","journal-title":"New Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jsps.2016.02.002_b0135","first-page":"444","article-title":"Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies (RECORD 1\u20134)","volume":"105","author":"Turpie","year":"2011","journal-title":"ThrombHaemost."},{"key":"10.1016\/j.jsps.2016.02.002_b0140","unstructured":"Xarelto (rivaroxaban), 2014. Prescribing Information. Janssen Pharmaceuticals, Inc., Titusville (NJ)."}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016416000141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016416000141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:31:04Z","timestamp":1736184664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319016416000141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1319016416000141"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2016.02.002","relation":{},"ISSN":["1319-0164"],"issn-type":[{"value":"1319-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of novel oral anticoagulant use within a community teaching hospital","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2016.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}]}}